The trial proved that nipocalimab reduced IgG antibodies, including anti-citrullinated protein autoantibodies, but the primary endpoint was missed.
Medscape Medical News
Source link
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Share This Article
